Drug intelligence / Profile preview

NI-003

Development stage: Preclinical
Lead developer: Neurimmune
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

NI-003 is a recombinant glycoprotein currently in preclinical development by NeuImmune for the treatment of inherited or acquired antithrombin deficiency. As a human-equivalent antithrombin replacement therapy, NI-003 is designed to restore the body's natural anticoagulant capacity. Antithrombin is a critical serine protease inhibitor that regulates the coagulation cascade by inactivating thrombin and Factor Xa. By supplementing deficient levels of this protein, NI-003 aims to prevent and treat thromboembolic complications in patients with quantitative or qualitative antithrombin defects.

Other names: Antithrombin ProgramAntithrombin (Human-Equivalent) program

Targets

F10 (Factor Xa)F2 (Thrombin)ATIII (Antithrombin III)

Beyond the preview

Go deeper on NI-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NI-003.

Explore the full profile